Federico J Mensa Selected Research

Antiviral Agents (Antivirals)

1/2021	Biomarkers for the clinical development of antiviral therapies.
1/2020	Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.
10/2019	Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.
8/2019	Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.
2/2019	Pharmacokinetics and safety of glecaprevir and pibrentasvir in HCV-negative subjects with hepatic impairment.
1/2019	Safety and efficacy of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C in patients aged 65 years or older.
1/2019	Efficacy and Pharmacokinetics of Glecaprevir and Pibrentasvir With Concurrent Use of Acid-Reducing Agents in Patients With Chronic HCV Infection.
1/2019	Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5,6): an open-label, multicentre, phase 3b trial.
1/2019	Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C virus infection.
1/2019	Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic HCV infection and psychiatric disorders: An integrated analysis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Federico J Mensa Research Topics

Disease

32	Infections 01/2021 - 01/2013
20	Fibrosis (Cirrhosis) 01/2020 - 02/2015
14	Chronic Hepatitis C 01/2019 - 08/2013
5	Liver Diseases (Liver Disease) 10/2019 - 10/2017
3	Virus Diseases (Viral Diseases) 01/2021 - 02/2015
2	COVID-19 03/2024 - 01/2023
2	Chronic Renal Insufficiency 10/2019 - 10/2017
1	Myocarditis (Carditis) 03/2024
1	Pericarditis 03/2024
1	Persistent Infection 01/2019
1	Mental Disorders (Mental Disorder) 01/2019
1	Flushing 01/2019
1	Nausea 01/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 02/2015
1	Anemia 01/2015
1	Exanthema (Rash) 01/2013
1	Asthenia 01/2013
1	Pruritus (Itching) 01/2013

Drug/Important Bio-Agent (IBA)

24	glecaprevir and pibrentasvirIBA 01/2020 - 01/2017
15	Ribavirin (Virazole)FDA LinkGeneric 10/2019 - 01/2013
14	Antiviral Agents (Antivirals)IBA 01/2021 - 01/2013
13	InterferonsIBA 01/2019 - 01/2013
12	glecaprevirIBA 10/2019 - 10/2016
11	pibrentasvirIBA 10/2019 - 10/2016
7	Protease Inhibitors (Protease Inhibitor)IBA 01/2018 - 08/2013
7	deleobuvirIBA 08/2016 - 01/2013
7	faldaprevirIBA 08/2016 - 01/2013
6	SofosbuvirIBA 01/2019 - 10/2017
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2019
2	NucleosidesIBA 08/2016 - 01/2015
1	Messenger RNA (mRNA)IBA 03/2024
1	mRNA VaccinesIBA 03/2024
1	BNT162 VaccineIBA 03/2024
1	VaccinesIBA 01/2023
1	P-300IBA 08/2019
1	AcidsIBA 01/2019
1	Immunosuppressive Agents (Immunosuppressants)IBA 01/2019
1	Tacrolimus (Prograf)FDA LinkGeneric 01/2019
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 01/2019
1	Reducing AgentsIBA 01/2019
1	daclatasvirIBA 01/2018
1	Proton Pump InhibitorsIBA 12/2017
1	trichostatin A (A 300)IBA 01/2017
1	Inosine TriphosphataseIBA 01/2015

Therapy/Procedure

8	Therapeutics 01/2019 - 08/2013
1	Opiate Substitution Treatment 01/2019
1	Retreatment 01/2019
1	Polypharmacy 01/2019
1	Duration of Therapy 01/2018